99 related articles for article (PubMed ID: 1771298)
1. Amelioration of doxorubicin resistance by pentoxifylline in human chronic myeloid leukemia cells in vitro.
Viladkar A; Juvekar A; Chitnis M; Advani S
Sel Cancer Ther; 1991; 7(3):119-26. PubMed ID: 1771298
[TBL] [Abstract][Full Text] [Related]
2. In vitro effects of pentoxifylline and doxorubicin on cell survival and DNA damage in sensitive and MDR-P388 leukemia cells.
Viladkar A; Chitnis M
Cancer Biother; 1994; 9(2):143-51. PubMed ID: 7812363
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of DNA biosynthesis by vincristine and pentoxifylline in murine P388 leukemia cells resistant to doxorubicin.
Chitnis MP; Viladkar AB; Juvekar AS
Neoplasma; 1990; 37(6):619-26. PubMed ID: 2274081
[TBL] [Abstract][Full Text] [Related]
4. Sensitization of P388 murine leukemia cells to epirubicin cytotoxicity by reserpine.
Viladkar A; Chitnis M
Cancer Biother; 1993; 8(1):77-85. PubMed ID: 7812352
[TBL] [Abstract][Full Text] [Related]
5. Dipyrone enhances intracellular accumulation and cytotoxicity of adriamycin in human chronic myeloid leukemia cells.
Chitnis MP; Kamath NS; Parekh HK; Advani SH
Neoplasma; 1991; 38(2):185-91. PubMed ID: 2041578
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of chronic myeloid leukemia cells to adriamycin cytotoxicity by clofibrate.
Parekh H; Satyamoorthy K; Advani S; Chitnis M
Tumori; 1990 Feb; 76(1):18-21. PubMed ID: 2321268
[TBL] [Abstract][Full Text] [Related]
7. Nicotinamide increases the sensitivity of chronic myeloid leukemia cells to doxorubicin via the inhibition of SIRT1.
Pan S; Leng J; Deng X; Ruan H; Zhou L; Jamal M; Xiao R; Xiong J; Yin Q; Wu Y; Wang M; Yuan W; Shao L; Zhang Q
J Cell Biochem; 2020 Jan; 121(1):574-586. PubMed ID: 31407410
[TBL] [Abstract][Full Text] [Related]
8. Pentoxifylline influences drug transport activity of P-glycoprotein and decreases mdrl gene expression in multidrug resistant mouse leukemic L1210/VCR cells.
Drobná Z; Stein U; Walther W; Barancík M; Breier A
Gen Physiol Biophys; 2002 Mar; 21(1):103-9. PubMed ID: 12168720
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone & adriamycin cytotoxicity enhanced by reserpine in human chronic myeloid leukaemia cells.
Chitnis MP; Kamath NS; Advani SH
Indian J Med Res; 1989 Jun; 90():197-202. PubMed ID: 2767744
[TBL] [Abstract][Full Text] [Related]
10. Role of the aclacinomycin A--doxorubicin association in reversal of doxorubicin resistance in K562 tumour cells.
Millot JM; Rasoanaivo TD; Morjani H; Manfait M
Br J Cancer; 1989 Nov; 60(5):678-84. PubMed ID: 2803945
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
[TBL] [Abstract][Full Text] [Related]
12. Single and combination treatment with vitamin K3 and adriamycin: in vitro effects on cell survival and DNA damage in human chronic myeloid leukemia cells.
Parekh H; Chavan S; Advani S; Chitnis M
Sel Cancer Ther; 1991; 7(3):127-35. PubMed ID: 1771299
[TBL] [Abstract][Full Text] [Related]
13. Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis.
Yang X; Pang J; Shen N; Yan F; Wu LC; Al-Kali A; Litzow MR; Peng Y; Lee RJ; Liu S
Oncotarget; 2016 Jun; 7(24):36382-36394. PubMed ID: 27144331
[TBL] [Abstract][Full Text] [Related]
14. Modulation of mitoxantrone cytotoxicity by verapamil in human chronic myeloid leukemia cells.
Satyamoorthy K; Chitnis MP; Pradhan SG; Advani SH
Oncology; 1989; 46(2):128-31. PubMed ID: 2710477
[TBL] [Abstract][Full Text] [Related]
15. Abrogation of human chronic myeloid leukemia cells insensitivity to adriamycin and mitoxanthrone cytotoxicity by quinidine.
Parekh HK; Advani SH; Chitnis MP
Neoplasma; 1990; 37(6):717-25. PubMed ID: 2274089
[TBL] [Abstract][Full Text] [Related]
16. Genotoxic effect of doxorubicin-transferrin conjugate on human leukemia cells.
Szwed M; Jozwiak Z
Mutat Res Genet Toxicol Environ Mutagen; 2014 Sep; 771():53-63. PubMed ID: 25308442
[TBL] [Abstract][Full Text] [Related]
17. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.
Xue C; Wang C; Liu Q; Meng Q; Sun H; Huo X; Ma X; Liu Z; Ma X; Peng J; Liu K
Tumour Biol; 2016 Jul; 37(7):8587-97. PubMed ID: 26733176
[TBL] [Abstract][Full Text] [Related]
18. Combination of Protoporphyrin IX-mediated Sonodynamic Treatment with Doxorubicin Synergistically Induced Apoptotic Cell Death of a Multidrug-Resistant Leukemia K562/DOX Cell Line.
Wang X; Jia Y; Su X; Wang P; Zhang K; Feng X; Liu Q
Ultrasound Med Biol; 2015 Oct; 41(10):2731-9. PubMed ID: 26166458
[TBL] [Abstract][Full Text] [Related]
19. Coupled delivery of imatinib mesylate and doxorubicin with nanoscaled polymeric vectors for a sustained downregulation of BCR-ABL in chronic myeloid leukemia.
Palamà IE; Cortese B; D'Amone S; Arcadio V; Gigli G
Biomater Sci; 2015 Feb; 3(2):361-72. PubMed ID: 26218127
[TBL] [Abstract][Full Text] [Related]
20. Effect of S9788, cyclosporin A and verapamil on intracellular distribution of THP-doxorubicin in multidrug-resistant K562 tumor cells, as studied by laser confocal microspectrofluorometry.
Sebille S; Morjani H; Poullain MG; Manfait M
Anticancer Res; 1994; 14(6A):2389-93. PubMed ID: 7825978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
